# Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dea-scheduling-benzodiazepine-analogs-schedule-i/ > **Published:** 2026-06-18T12:05:29-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:24:41-04:00 > **Clinical Summary:** Learn about DEA scheduling benzodiazepine analogs like clonazolam and etizolam in Schedule I, addressing risks from synthetic benzodiazepines and regulatory updates. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA schedulingcannabis legislation[medical cannabis access](https://cedclinic.com/medical-marijuana-card-reciprocity/) Clinical Summary The Drug Enforcement Administration has placed five benzodiazepine analogs (clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam) into Schedule I of the Controlled Substances Act, recognizing their abuse potential and lack of accepted medical use. These synthetic benzodiazepines have proliferated in illicit drug markets as unregulated alternatives to prescription benzodiazepines, often marketed as “research chemicals” or sold online, and have been associated with overdoses and adverse health events comparable to or exceeding those of regulated benzodiazepines. The scheduling action addresses a significant gap in drug control policy, as these substances previously exploited regulatory loopholes by being chemically distinct from listed benzodiazepines while producing identical pharmacological effects and clinical risks. Clinicians should be aware that patients may be exposed to these dangerous compounds through illicit channels, and healthcare providers need to maintain vigilance for benzodiazepine-like intoxication or withdrawal syndromes that may not correspond to prescribed medications. The practical implication for clinicians is to screen patients for use of these novel psychoactive substances during substance use assessments and to recognize that benzodiazepine-related symptoms may stem from unregulated synthetic analogs requiring similar medical management but with heightened toxicity concerns. Clinical Perspective 💊 The recent scheduling of several novel benzodiazepine analogs (clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam) as Schedule I controlled substances addresses an important gap in regulatory oversight of designer drugs that have proliferated in underground markets. These synthetic benzodiazepines pose particular clinical concern because they are often sold as unregulated products with unknown purity and potency, creating risks for accidental overdose, dependence, and dangerous drug interactions that patients may not disclose or even recognize. The regulatory action reflects legitimate [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) efforts to prevent misuse, though clinicians should recognize that Schedule I placement does not eliminate patient exposure, as these agents continue to circulate in illicit channels and may be encountered in cases of acute intoxication or withdrawal. Equally important is the reality that scheduling decisions occur slowly relative to drug innovation, meaning new analogs 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Clonazolam%2C+Diclazepam%2C+Etizolam%2C+Flualprazolam%2C+an...+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F03%2F02%2F2026-04112%2Fschedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F03%2F02%2F2026-04112%2Fschedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Clonazolam%2C+Diclazepam%2C+Etizolam%2C+Flualprazolam%2C+an...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F03%2F02%2F2026-04112%2Fschedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - [Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://cedclinic.com/temporary-scheduling-novel-benzodiazepines-bromazolam-update/) - [Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I](https://cedclinic.com/3-meo-pcp-schedule-i-dea-controlled-substance/) - [Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) 📰 Source: [https://www.federalregister.gov/documents/2026/03/02/2026-04112/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and](https://www.federalregister.gov/documents/2026/03/02/2026-04112/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act](https://cedclinic.com/dea-scheduling-benzodiazepine-analogs-2026/) Detailed overview of the DEA’s placement of five benzodiazepine analogs into Schedule I, highlighting regulatory and clinical considerations. [Read More](https://cedclinic.com/dea-scheduling-benzodiazepine-analogs-2026/) Schedules of Controlled Substances: Placement of Diphenidine in Schedule I Explore the DEA’s scheduling of Diphenidine in Schedule I and its implications for drug control and clinical practice. Explore Article [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) Review the temporary scheduling of 2-Fluorodeschloroketamine in Schedule I and its impact on regulatory and clinical frameworks. [Learn More](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).